Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis-Reference-Cited by-同舟云学术

Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis

Published:2022-06-21 Issue:1 Volume:52 Page:71-86
ISSN:0300-5771
Container-title:International Journal of Epidemiology
language:en
Short-container-title:

Author:

Watts Eleanor L¹^ORCID,Perez-Cornago Aurora¹^ORCID,Fensom Georgina K¹,Smith-Byrne Karl²,Noor Urwah¹,Andrews Colm D¹,Gunter Marc J³,Holmes Michael V⁴⁵^ORCID,Martin Richard M⁶⁷⁸,Tsilidis Konstantinos K⁹¹⁰,Albanes Demetrius¹¹,Barricarte Aurelio¹²¹³¹⁴,Bueno-de-Mesquita H Bas¹⁵,Cohn Barbara A¹⁶,Deschasaux-Tanguy Melanie¹⁷^ORCID,Dimou Niki L³,Ferrucci Luigi¹⁸,Flicker Leon¹⁹²⁰^ORCID,Freedman Neal D¹¹,Giles Graham G²¹²²²³^ORCID,Giovannucci Edward L²⁴²⁵²⁶^ORCID,Haiman Christopher A²⁷,Hankey Graham J¹⁹,Holly Jeffrey M P²⁸,Huang Jiaqi¹¹²⁹^ORCID,Huang Wen-Yi¹¹^ORCID,Hurwitz Lauren M¹¹,Kaaks Rudolf³⁰,Kubo Tatsuhiko³¹,Le Marchand Loic³²,MacInnis Robert J²²²³,Männistö Satu³³,Metter E Jeffrey³⁴,Mikami Kazuya³⁵,Mucci Lorelei A²⁴,Olsen Anja W³⁶³⁷^ORCID,Ozasa Kotaro³⁸^ORCID,Palli Domenico³⁹,Penney Kathryn L²⁴²⁵,Platz Elizabeth A⁴⁰^ORCID,Pollak Michael N⁴¹,Roobol Monique J⁴²,Schaefer Catherine A⁴³,Schenk Jeannette M⁴⁴,Stattin Pär⁴⁵^ORCID,Tamakoshi Akiko⁴⁶,Thysell Elin⁴⁷,Tsai Chiaojung Jillian⁴⁸,Touvier Mathilde¹⁷^ORCID,Van Den Eeden Stephen K⁴³⁴⁹,Weiderpass Elisabete⁵⁰^ORCID,Weinstein Stephanie J¹¹,Wilkens Lynne R³²,Yeap Bu B¹⁹⁵¹,Eeles Rosalind A,Haiman Christopher A,Kote-Jarai Zsofia,Schumacher Fredrick R,Benlloch Sara,Olama Ali Amin Al,Muir Kenneth R,Berndt Sonja I,Conti David V,Wiklund Fredrik,Chanock Stephen,Wang Ying,Tangen Catherine M,Batra Jyotsna,Clements Judith A,Allen Naomi E⁴⁵²,Key Timothy J¹,Travis Ruth C¹,

Affiliation:

1. Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford , Oxford, UK

2. Genomic Epidemiology Branch, International Agency for Research on Cancer , Lyon, France

3. Section of Nutrition and Metabolism, International Agency for Research on Cancer , Lyon, France

4. Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford , Oxford, UK

5. Medical Research Council Population Health Research Unit, University of Oxford , Oxford, UK

6. Department of Population Health Sciences, Bristol Medical School, University of Bristol , Bristol, UK

7. MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol , Bristol, UK

8. National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and Weston NHS Foundation Trust and University of Bristol , Bristol, UK

9. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London , London, UK

10. Department of Hygiene and Epidemiology, University of Ioannina School of Medicine , Ioannina, Greece

11. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA

12. Group of Epidemiology of Cancer and Other Chronic Diseases, Navarra Public Health Institute , Pamplona, Spain

13. Group of Epidemiology of Cancer and Other Chronic Diseases, Navarra Institute for Health Research (IdiSNA) , Pamplona, Spain

14. CIBER Epidemiology and Public Health CIBERESP , Madrid, Spain

15. Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM) , Utrecht, The Netherlands

16. Child Health and Development Studies, Public Health Institute , Berkeley, CA, USA

17. Sorbonne Paris Nord University, Nutritional Epidemiology Research Team, Epidemiology and Statistics Research Center, University of Paris , Bobigny, France

18. National Institute on Aging , Baltimore, MD, USA

19. WA Centre for Health & Ageing, Medical School, University of Western Australia , Perth, WA, Australia

20. Western Australian Centre for Health and Ageing, University of Western Australia , Perth, WA, Australia

21. Cancer Epidemiology Division, Cancer Council Victoria , Melbourne, VIC, Australia

22. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne , Melbourne, VIC, Australia

23. Precision Medicine, School of Clinical Sciences at Monash Health, Monash University , Melbourne, VIC, Australia

24. Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, MA, USA

25. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School , Boston, MA, USA

26. Department of Nutrition, Harvard T.H. Chan School of Public Health , Boston, MA, USA

27. Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center , Los Angeles, CA, USA

28. IGFs & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, University of Bristol , Bristol, UK

29. National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, Second Xiangya Hospital of Central South University , Changsha, Hunan, China

30. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ) , Heidelberg, Germany

31. Department of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima, Japan

32. University of Hawaii, Cancer Center , Honolulu, HI, USA

33. Department of Public Health and Welfare, Finnish Institute for Health and Welfare , Helsinki, Finland

34. Department of Neurology, College of Medicine, University of Tennessee Health Science Center , Memphis, TN, USA

35. Departmemt of Urology, Japanese Red Cross Kyoto Daiichi Hospital , Kyoto, Japan

36. Department of Public Health, Aarhus University , Aarhus, Denmark

37. Danish Cancer Society, Research Center , Copenhagen, Denmark

38. Departmemt of Epidemiology, Radiation Effects Research Foundation , Hiroshima, Japan

39. Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network , Florence, Italy

40. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD, USA

41. Departments of Medicine and Oncology, McGill University , Montreal, QC, Canada

42. Department of Urology, Erasmus University Medical Center , Rotterdam, The Netherlands

43. Division of Research, Kaiser Permanente Northern California , Oakland, CA, USA

44. Cancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center , Seattle, WA, USA

45. Department of Surgical Sciences, Uppsala University , Uppsala, Sweden

46. Department of Public Health, Faculty of Medicine, Hokkaido University , Sapporo, Japan

47. Department of Medical Biosciences, Umeå University , Umeå, Sweden

48. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center , New York, NY, USA

49. Department of Urology, University of California San Francisco , San Francisco, CA, USA

50. Director’s Office, International Agency for Research on Cancer, World Health Organization , Lyon, France

51. Department of Endocrinology and Diabetes, Fiona Stanley Hospital , Perth, WA, Australia

52. UK Biobank Ltd , Stockport, UK

Abstract

Abstract Background Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer. Methods Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium. Results In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I. Conclusions These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.

Funder

Cancer Research UK

Nuffield Department of Population Health Early Career Research Fellowship

Cancer Research UK Population Research Fellowship

World Cancer Research Fund

World Cancer Research Fund International

National Institutes of Health

National Cancer Institute

American Institute for Cancer Research

National Health and Medical Research Council of Australia

Grants-in-Aid for Scientific Research

Ministry of Education, Culture, Sports, Science and Technology